You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 196241 - 196250 of 207725 results
  1. Digital health for medication adherence among African Americans with hypertension

    SBC: Environment And Health Group, Inc.            Topic: 102

    Abstract: Under the leadership of Patricia Weitzman, PhD, a multicultural, multidisciplinary team of clinicians and researchers will collaborate to develop, formatively test, and evaluate the short-effectiveness of a digital provider platform, called Memento.HTN, that is integrated with a patient SMS text system, and designed to support medication adherence by African Americans with hypertension ( ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  2. Flow Responsive Embolic Agent for the Complete Devascularization of Meningiomas

    SBC: ARSENAL MEDICAL INC            Topic: 102

    PROJECT SUMMARY Significance: Pre-operative embolization (POE) of meningiomas is an established neuroendovascular procedure performed to reduce the extensive amount of blood loss that occurs during tumor resection. The current practice is significantly hampered because of efficacy and safety deficiencies of current embolic agents used off-label for this indication (none of which are designed speci ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  3. Identification of bactericidal antibody specificities for the development of novel broad-coverage vaccine candidates against Neisseria meningitidis

    SBC: ImmPORT Therapeutics Inc dba Antigen Discovery Inc            Topic: NIAID

    ABSTRACT Neisseria meningitidis (Nm) is a Gram-negative bacterium that commonly colonizes the human pharyngeal mucosa, but can also cause invasive meningococcal disease (IMD), a devastating disease that presents as septicemia and meningitis. More than 70,000 cases of IMD are reported annually worldwide with case fatality ratios between 5% and 15%. Bactericidal anti-Nm antibodies may prevent infect ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  4. Development of Nav1.7 Selective Inhibitors for the Treatment of Chronic Cough

    SBC: SITEONE THERAPEUTICS, INC.            Topic: NHLBI

    PROJECT SUMMARYChronic cough, or cough that persists for more than eight weeks, is a condition that is often associated with diseases such as chronic obstructive pulmonary disorder (COPD), asthma, idiopathic pulmonary fibrosis, bronchiectasis or gastroesophageal reflux disease (GERD). In other cases, the etiology is unknown, although it has been noted that the cough often first arises following a ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. "Blueprint of Life" Genomic Literacy Tool: An interactive to enhance genetic and genomic understanding with middle/high school students and their teachers through personal genetics and human disease

    SBC: D'Vinci Interactive, Inc.            Topic: 500

    The increasing prevalence of genetics and genomics information in modern life calls for an equally relevant and engaging solution to teach the next generation. Additionally, educational interventions that help close the participation and achievement gap of underrepresented demographic groups in STEM are sorely needed. In this NIGMS Phase II SBIR project, d’Vinci Interactive, in collaboration wit ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  6. Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome

    SBC: CARTESIAN THERAPEUTICS INC            Topic: NHLBI

    ABSTRACT This application is to support a clinical trial of the first mRNA engineered cell therapy for Acute Respiratory Distress Syndrome (ARDS), including ARDS caused by COVID-19. The FDA has already reviewed the IND application and determined that the study may proceed. ARDS is a severe inflammatory respiratory failure that kills an estimated 80,000 Americans each year. 80% of ARDS patients req ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a Treatment for Eosinophil-Mediated Allergic Inflammatory Diseases Utilizing a Neutralizing Agent Targeting Eosinophil Granule Major Basic Protein

    SBC: NexEos Diagnostics, Inc            Topic: NIAID

    ABSTRACT The eosinophil is a peripheral blood leukocyte containing an abundance of cytoplasmic granules, rich in cationic protein toxins. Among these, the most abundant on a molar basis is the major basic protein-1, eMBP1. eMBP1 kills helminths, bacteria, and numerous cells, such as respiratory epithelium, but also activates cells, including basophils and mast cells. Studies of human diseases show ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  8. The hCNS-HIV/ARV assay system, a platform utilizing human iPSC-neurons/-microglia/-astrocytes to test HIV/AIDS therapeutics for neurotoxicity related to HIV-associated cognitive disroder (HAND)

    SBC: VALA SCIENCES, INC.            Topic: 105

    Globally, about 40 million people live with HIV/AIDS, and HIV antiretroviral agents (ARVs) are a multi-billion dollar pharmaceutical sector with continued development of agents. Thanks to combination antiretroviral therapy (cART, in which 2 to 4 ARVs are given, simultaneously) HIV+ people have a near-normal life-span. HIV+ pregnant women also receive cART, and their children are given cART prophyl ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  9. Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy

    SBC: Epigen Biosciences, Inc.            Topic: 200

    PROJECT SUMMARY Diabetic neuropathy (DPN) is a major unmet health concern where over half of the estimated 33 million people in the US with type 1 or type 2 diabetes will develop neuropathy1. There is no FDA-approved disease modifying treatment for preventing or slowing progression of diabetic neuropathy other than a recommendation to maintain glycemic control2 and current treatments are restricte ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic antibodies for treating chemotherapy induced peripheral neuropathic pain

    SBC: ABALONE BIO, INC.            Topic: NCI

    ABSTRACT Chemotherapy-induced peripheral neuropathy (CIPN) is an often long-lasting neurological condition that arises frequently in cancer patients who receive broadly used chemotherapies such as taxanes. CIPN causes abnormal pain and other symptoms that can limit chemotherapy dosage and significantly impact quality of life for years. There are no drugs that prevent CIPN or treat it well. Duloxet ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government